Suchergebnisse - "Xia, Zhongjun"

PubPharm (66)

41

A Modified NHL-BFM-95 Regimen Produces Better Outcome Than HyperCVAD in Adult Patients with T-Lymphoblastic Lymphoma, a Two-Institution Experience

enthalten in: Cancer research and treatment | 2020

von Li, C. | Wuxiao, Z. | Chen, X. | +5

42

Long-term outcomes of modified BFM-95 regimen in adults with newly diagnosed standard-risk acute lymphoblastic leukemia : a retrospective single-center study

enthalten in: International journal of hematology | 2019

von Li, C. | Cai, X. | Chen, X. | +3

43

Long-term outcomes of modified BFM-95 regimen in adults with newly diagnosed standard-risk acute lymphoblastic leukemia: a retrospective single-center study

enthalten in: International journal of hematology | 2019

von Li, C. | Cai, X. | Chen, X. | +3

44

Long-term outcomes of modified BFM-95 regimen in adults with newly diagnosed standard-risk acute lymphoblastic leukemia: a retrospective single-center study

enthalten in: International journal of hematology | 2019

von Li, C. | Cai, X. | Chen, X. | +3

45

High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma

enthalten in: Translational oncology | 2018

von Guo, X. | Wang, J. | Jin, J. | +7

46

Increased interleukin-17A levels promote rituximab resistance by suppressing p53 expression and predict an unfavorable prognosis in patients with diffuse large B cell lymphoma

enthalten in: International journal of oncology | 2018

von Zhong, W. | Xu, X. | Zhu, Z. | +8

47

Association between extranodal natural killer/T-cell lymphoma and hepatitis B viral infection : a case-control study

enthalten in: Journal of Cancer | 2017

von Wang, K. | Yang, H. | He, W. | +7

48

Cancer pain management in China : current status and practice implications based on the ACHEON survey

enthalten in: Journal of pain research | 2017

von Xia, Z.

49

Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells In Vitro, In Vivo, and Ex Vivo

enthalten in: Molecular cancer therapeutics | 2016

von Chen, Z. | Chen, Y. | Xu, M. | +8

50

Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer

enthalten in: BMC cancer | 2016

von Sun, Y. | Cheng, Y. | Hao, X. | +16